TD Cowen raised the firm’s price target on Bruker (BRKR) to $53 from $42 and keeps a Hold rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies “already soft guided” 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target raised to $53 from $45 at Guggenheim
- RI Research secures orders for enabling subsystems for gamma ray source of ELI
- AbCellera to receive $36M upfront in patent litigation settlement with Bruker
- Bruker price target raised to $60 from $43 at BofA
- Bruker price target raised to $55 from $50 at JPMorgan